🔗 Share this article

As America proceeds with unprecedented changes to its vaccine recommendations, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines throughout the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Schedule

Health officials were set to announce radical revisions to the childhood vaccine schedule recently, synchronizing the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with much of the global community with little proof for benefit. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to present at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

A Shift at the FDA

This interim role might represent a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood immunization guidelines in the US to become more like the Danish model, a nation with universal health coverage and a citizenry roughly the population of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been customary for past leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have the necessary background” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Former heads of the center would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that prior appointees who ran the center have had.”

This division has an vast portfolio at the agency, Woodcock emphasized.

“Many people just pays attention on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and more, and every single one have to be managed,” Woodcock explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major administrative element to the job, which supervises more than 5,000 personnel. “It is a huge management job, if you execute it properly,” the former official concluded.

Agency Reaction and Controversial Programs

In response to concerns about Dr. Høeg's credentials and whether this appointment represents greater collaboration among regulatory chiefs on immunizations, a spokesperson said that the “concerns rely on flawed presumptions”.

“Her experience matches the responsibilities of her role,” the spokesperson said, noting the months Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a controversial rapid medication authorization process that allegedly worried her predecessors. “How are these drugs being chosen for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he said, “the FDA looks to be trending towards less stringent rules of all drugs, aside from immunizations.”

Public History on Immunizations

Regarding immunizations, Høeg has a clearer, if problematic, track record, critics observe. She published a analysis using non-validated public submissions to estimate the frequency of heart inflammation after COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the current government encompassed revising rules for recently developed shots and halting “non-essential” vaccines, she stated following the vote on a audio program. At the FDA, Høeg has reportedly suggested preventing teenage boys from receiving COVID-19 vaccines.

“She’s an all-around dogmatist who commences with her preconceived notions and reverse-engineers to accommodate the evidence in a highly misleading, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|